Search company, investor...

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price




About Zymeworks

Zymeworks is a clinical-stage biopharmaceutical company that operates in the healthcare sector, with a focus on the development of next-generation multifunctional biotherapeutics. The company's main offerings include the development of novel medicines for patients with difficult-to-treat cancers and other serious diseases, utilizing their suite of therapeutic platforms and fully integrated drug development engine. Zymeworks primarily sells to the healthcare industry, specifically targeting areas of high unmet medical need. It was founded in 2004 and is based in Vancouver, British Columbia.

Headquarters Location

1385 West 8th Avenue Suite 540

Vancouver, British Columbia, V6H 3V9,





Zymeworks Patents

Zymeworks has filed 104 patents.

The 3 most popular patent topics include:

  • monoclonal antibodies
  • clusters of differentiation
  • immunology
patents chart

Application Date

Grant Date


Related Topics




Drug discovery, Trifluoromethyl compounds, Peptides, V8SuperTourer drivers, Amines


Application Date


Grant Date



Related Topics

Drug discovery, Trifluoromethyl compounds, Peptides, V8SuperTourer drivers, Amines



Latest Zymeworks News

Vor shares new data for stem cell therapy; Melinta partners with Venatorx on antibiotic under FDA review

Nov 10, 2023

Plus, news about BeiGene, Zymeworks, Rz­nomics, and Adicet: Vor Bio shares ear­ly da­ta for its gene-edit­ed stem cell ther­a­py: The com­pa­ny an­nounced Thurs­day that its stem cell treat­ment seemed to en­graft nor­mal­ly in sev­en pa­tients with acute myeloid leukemia (AML) treat­ed so far. Three pa­tients who re­ceived My­lotarg — Pfiz­er’s AML drug — saw “pro­tec­tion from deep cy­tope­nias,” or a steep drop in blood cell counts that’s of­ten seen as a side ef­fect of the drug. My­lotarg tar­gets CD33, an anti­gen found in high lev­els on leukemia cells but al­so ex­pressed in some nor­mal cells. Vor, found­ed on re­search led by Sid­dhartha Mukher­jee, ed­its CD33 out of donor stem cells with the goal of spar­ing pa­tients from the treat­ment’s side ef­fects. More da­ta are set to be pre­sent­ed at ASH, the com­pa­ny an­nounced last week. — Lei Lei Wu Unlock this article instantly by becoming a free subscriber. You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news. SIGN UP

Zymeworks Frequently Asked Questions (FAQ)

  • When was Zymeworks founded?

    Zymeworks was founded in 2004.

  • Where is Zymeworks's headquarters?

    Zymeworks's headquarters is located at 1385 West 8th Avenue, Vancouver.

  • What is Zymeworks's latest funding round?

    Zymeworks's latest funding round is IPO.

  • How much did Zymeworks raise?

    Zymeworks raised a total of $146.87M.

  • Who are the investors of Zymeworks?

    Investors of Zymeworks include CTI Life Sciences Fund, Eli Lilly and Company, Fonds de Solidarite FTQ, Northleaf Capital Partners, Merlin Nexus and 11 more.

  • Who are Zymeworks's competitors?

    Competitors of Zymeworks include Oligomerix, ADV Bioscience, PhaseBio Pharmaceuticals, Dyax, Mirna Therapeutics and 7 more.


Compare Zymeworks to Competitors

Bolder BioTechnology

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.

Synaptic Research

Synaptic Research LLC is a biotechnology company which conducts research and develops products based on naturally-occurring large protein molecules. Specifically, the company engineers proteins derived from toxins which affect the synaptic junction. A well-known example of such a protein is the Botulinum Neurotoxin, or BoNT. This protein has qualities of targeting and persistence which make it an excellent candidate for further engineering and development of therapeutic and pharmaceutical products.

Dialectica srl

Dialectica offers Neural Stem Cell-based Systems and Assays for drug screening in neurodegenerative diseases. The mission of Dialectica is to add value to the link between research and pharmaceutical and biotechnology companies that are active in the discovery of therapeutics for brain diseases. Dialectica develops and optimize Neural Stem Cell-based Systems and Assays for drug screening in neurodegenerative diseases.


Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company's strategy is to develop new drugs that it derives from natural substances used therapeutically in non-western medical practice. Bionovo's first drug is entering phase II clinical testing for menopause, its second has completed phase I clinical testing for cancer, and these are followed by more than forty additional drug candidates that the company believes should provide Bionovo with a sustainable development pipeline of new chemical entities and botanicals.

Trellis Bioscience

Trellis Bioscience provides healthcare products and services. The Company develops treatments for infectious diseases and oncology indications such as therapeutic antibody treatments. The company was founded in 1998 and is based in Redwood City, California.

BioPro Pharmaceutical

BioPro Pharmaceutical is the first regional biotech company in Asia to develop, market leading biopharmaceutical medicines, as well as many of the world's best known biopharmaceutical products. BioPro Pharmaceutical , Inc. has infrastructure in place in all major countries in Asia to target the market of US$30 billion. BioPro's expertise is in providing creative pharmaceutical solutions to small and medium-sized US or European companies by integrating Asia's respective business strengths in addressing the pharmaceutical needs of the Asia-Pacific region. We have the knowledge and know-how of the clinical and regulatory requirements across the Asian region . We manage more than 600 professional sales representatives. We are focused on the marketing and distribution of innovative biotech cancer products in Asian markets with the most cost-effective approaches. We anticipate intense competition in this new market sector, and are working diligently to stay at the forefront of this everchanging competitive environment. BioPro obtained the exclusive rights for the core patented technology - High Throughput Mammalian Protein Expression technology to develop cost effective protein products for bioassay and reagent support and " rapid mammalian production cell development technology and downstream support team for new generations of currently well-known and future protein drugs; We have three protein therapeutics, two antibody therapeutics and two vaccines under development.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.